BR112017020739B1 - Compostos fundidos tricíclicos de 1-cicloalquil piridin-2-ona, composição farmacêutica e seus usos - Google Patents

Compostos fundidos tricíclicos de 1-cicloalquil piridin-2-ona, composição farmacêutica e seus usos Download PDF

Info

Publication number
BR112017020739B1
BR112017020739B1 BR112017020739-7A BR112017020739A BR112017020739B1 BR 112017020739 B1 BR112017020739 B1 BR 112017020739B1 BR 112017020739 A BR112017020739 A BR 112017020739A BR 112017020739 B1 BR112017020739 B1 BR 112017020739B1
Authority
BR
Brazil
Prior art keywords
oxo
methyl
methoxy
alkyl
pyrido
Prior art date
Application number
BR112017020739-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017020739A2 (pt
Inventor
Saravanan Vadivelu
Sridharan Rajagopal
Murugan CHINNAPATTU
Pavan Kumar Gondrala
Dhanalakshmi Sivanandhan
Chandrika Mulakala
Original Assignee
Jubilant Biosys Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Biosys Limited filed Critical Jubilant Biosys Limited
Publication of BR112017020739A2 publication Critical patent/BR112017020739A2/pt
Publication of BR112017020739B1 publication Critical patent/BR112017020739B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017020739-7A 2015-03-30 2016-03-30 Compostos fundidos tricíclicos de 1-cicloalquil piridin-2-ona, composição farmacêutica e seus usos BR112017020739B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1636CH2015 2015-03-30
IN1636/CHE/2015 2015-03-30
PCT/IN2016/050098 WO2016157221A1 (en) 2015-03-30 2016-03-30 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer

Publications (2)

Publication Number Publication Date
BR112017020739A2 BR112017020739A2 (pt) 2018-07-17
BR112017020739B1 true BR112017020739B1 (pt) 2023-03-14

Family

ID=56015058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020739-7A BR112017020739B1 (pt) 2015-03-30 2016-03-30 Compostos fundidos tricíclicos de 1-cicloalquil piridin-2-ona, composição farmacêutica e seus usos

Country Status (16)

Country Link
US (2) US10689390B2 (cg-RX-API-DMAC7.html)
EP (1) EP3277683B1 (cg-RX-API-DMAC7.html)
JP (1) JP6764877B2 (cg-RX-API-DMAC7.html)
KR (1) KR102588109B1 (cg-RX-API-DMAC7.html)
CN (1) CN107548393B (cg-RX-API-DMAC7.html)
AU (1) AU2016242473B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020739B1 (cg-RX-API-DMAC7.html)
CA (1) CA2980266C (cg-RX-API-DMAC7.html)
DK (1) DK3277683T3 (cg-RX-API-DMAC7.html)
ES (1) ES2911886T3 (cg-RX-API-DMAC7.html)
IL (1) IL254528B (cg-RX-API-DMAC7.html)
MX (1) MX376112B (cg-RX-API-DMAC7.html)
PL (1) PL3277683T3 (cg-RX-API-DMAC7.html)
PT (1) PT3277683T (cg-RX-API-DMAC7.html)
RU (1) RU2721120C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016157221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61803B1 (sr) * 2015-09-09 2021-06-30 Jubilant Biosys Ltd Triciklični fuzioni piridin-2-on derivati i njihova upotreba kao inhibitora brd4
RU2019117356A (ru) * 2016-11-10 2020-12-10 Лосинь Фармасьютикал (Шанхай) Ко., Лтд. Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение
CN111819181A (zh) * 2018-05-10 2020-10-23 罗欣药业(上海)有限公司 苯并七元杂环类化合物、其制备方法、药物组合物及应用
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1545767A (en) * 1976-06-30 1979-05-16 Aspro Nicholas Ltd Isoquinoline derivatives
WO2008133288A1 (ja) 2007-04-25 2008-11-06 Daiichi Sankyo Company, Limited 三環性アリール化合物
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
EP2585465B1 (en) 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2901352A1 (en) * 2013-02-19 2014-08-28 Bayer Pharma Aktiengesellschaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
BR112015022391B1 (pt) * 2013-03-12 2021-12-21 Abbvie Inc Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9814728B2 (en) * 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)

Also Published As

Publication number Publication date
RU2017135205A3 (cg-RX-API-DMAC7.html) 2019-07-17
KR20170132278A (ko) 2017-12-01
IL254528A0 (en) 2017-11-30
CA2980266C (en) 2025-05-06
IL254528B (en) 2020-11-30
US20180282345A1 (en) 2018-10-04
RU2017135205A (ru) 2019-04-10
AU2016242473A1 (en) 2017-10-26
US20200331926A1 (en) 2020-10-22
MX2017012387A (es) 2018-06-11
AU2016242473B2 (en) 2020-06-25
KR102588109B1 (ko) 2023-10-12
MX376112B (es) 2025-03-07
JP2018510203A (ja) 2018-04-12
US11319326B2 (en) 2022-05-03
HK1248686A1 (zh) 2018-10-19
DK3277683T3 (en) 2022-05-02
CN107548393A (zh) 2018-01-05
EP3277683B1 (en) 2022-03-09
ES2911886T3 (es) 2022-05-23
EP3277683A1 (en) 2018-02-07
CN107548393B (zh) 2021-03-02
US10689390B2 (en) 2020-06-23
NZ735972A (en) 2024-08-30
JP6764877B2 (ja) 2020-10-07
BR112017020739A2 (pt) 2018-07-17
PT3277683T (pt) 2022-06-28
PL3277683T3 (pl) 2022-05-23
CA2980266A1 (en) 2016-10-06
WO2016157221A1 (en) 2016-10-06
RU2721120C2 (ru) 2020-05-15

Similar Documents

Publication Publication Date Title
US11267820B2 (en) Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors
ES2823477T3 (es) Aril éteres y usos de los mismos
US11319326B2 (en) Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer
ES2737148T3 (es) Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
CA2926596C (en) Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
WO2016140501A1 (en) Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
HK1248686B (en) Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer
BR112018004338B1 (pt) Derivados de piridin-2-ona tricíclica fundida, composição, método e seu uso como inibidores de brd4
HK1251562B (en) Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2016, OBSERVADAS AS CONDICOES LEGAIS